ImmuCell Corporation (ICCC)
| Market Cap | 79.45M |
| Revenue (ttm) | 14.54M |
| Net Income (ttm) | -1.34M |
| Shares Out | 7.22M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $10.07 |
| Previous Close | $9.99 |
| Change ($) | 0.08 |
| Change (%) | 0.80% |
| Day's Open | 10.12 |
| Day's Range | 9.95 - 10.09 |
| Day's Volume | 1,377 |
| 52-Week Range | 4.42 - 13.20 |
PORTLAND, Maine, May 19, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...
PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...
Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET
PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
PORTLAND, Maine , Feb. 22, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET
PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript
Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET
PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2020 Results - Earnings Call Transcript
Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET
PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
PORTLAND, Maine, June 16, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript
PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products tha...
PORTLAND, Maine, May 14, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets scientifica...
ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020
PORTLAND, Maine, April 02, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifi...
PORTLAND, Maine, March 11, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifi...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript
PORTLAND, Maine, Feb. 19, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019
PORTLAND, Maine, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2019 Results - Earnings Call Transcript
PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scienti...
PORTLAND, Maine, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientif...
Second Submission Anticipated Around Q3 2020
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2019 Results - Earnings Call Transcript
ImmuCell Corporation's (ICCC) CEO Michael Brigham on Q1 2019 Results - Earnings Call Transcript
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, ... [Read more...]
| Industry Biotechnology | IPO Date Apr 30, 1987 |
| CEO Michael Brigham | Employees 52 |
| Stock Exchange NASDAQ | Ticker Symbol ICCC |
Financial Performance
In 2020, ImmuCell's revenue was $15.34 million, an increase of 11.80% compared to the previous year's $13.72 million. Losses were -$1.02 million, -21.11% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for ImmuCell stock is "Strong Buy" and the 12-month stock price forecast is 14.00.